The U.S. Department of Health & Human Services (HHS) made headlines in recent weeks, recommending marijuana be reclassified from Schedule I to Schedule III under federal law. So, what will this mean for the cannabis market in 2024? Join us as we look at the science, policy and business issues at the center of this momentous development.
Register Below!⬇⬇
https://www.benzinga.com/events/reclassifying-cannabis/?preview=true
———————————————————————————————————————————————————–
Opening Remarks
Matt Steinmetz
Fireside:
David Traylor, Senior Managing Director – Golden Eagle Partners
Hunter Land, PhD; VP Research & Development – Biopharmaceutical Research Company Inc.
Eric Berlin, Partner – Dentons
David Mangone, Director of Policy & Government Affairs – The Liaison Group
Pablo Zuanic, Managing Partner – Zuanic & Associates
Moderator: Javier Hasse, Managing Editor – Benzinga Cannabis
Closing Remarks
Matt Steinmetz
———————————————————————————————————————————————————–
Check out www.benzinga.com for complete coverage and all the latest financial news and data!
Follow us Online!
📸Instagram: www.instagram.com/benzinga
👍Facebook: www.facebook.com/Benzinga
📱TikTok: www.tiktok.com/@benzinga
🐤Twitter: twitter.com/Benzinga
Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.
#Benzinga #Webinar #Cannabis
source
